Artiva details wind-down cost estimates after scrapping AlloNK program
The company now pegs total charges from its workforce cut and trial shutdown at $27 million to $35 million, with most costs expected in Q4 2026.
SEC filing
2 stories
The company now pegs total charges from its workforce cut and trial shutdown at $27 million to $35 million, with most costs expected in Q4 2026.
SEC filing
The company stopped work on its lead NK cell therapy after two patient deaths and weak durability data, and is now reviewing strategic options including a possible sale or dissolution.
SEC filing (4)